Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 19/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KDM6B | O15054 | 1/20 | 0.38 |
| ▸ | TET3 | O43151 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | KDM5C | P41229 | 1/20 | 0.38 |
| ▸ | ASPH | Q12797 | 1/20 | 0.38 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.38 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.38 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.38 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.38 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.38 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.38 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL31345935 | 0.98 | KMO (0.49) | KMOKDM4EKDM6BTET3KDM4A | |
| SCHEMBL163294 | 0.80 | KDM4E (0.37) | KMOKDM4EKDM5AKDM5CKDM5B | |
| Hydrochloric Acid SCHEMBL8170615 | 0.78 | SORD (0.44) | KMOKDM4EALDH1A1 | |
| SCHEMBL31126262 | 0.77 | KDM4E (0.55) | KMOKDM4EKDM6BTET3KDM4A | |
| SCHEMBL87765 | 0.77 | KDM4E (0.55) | KMOKDM4EKDM6BTET3KDM4A | |
| SCHEMBL163539 | 0.77 | KMO (0.50) | KMO | |
| SCHEMBL23774539 | 0.76 | KMO (0.49) | KMOKDM4EKDM6BTET3KDM4A | |
| Fluoride SCHEMBL21332111 | 0.76 | KDM4E (0.53) | KMOKDM4EKDM6BTET3KDM4A | |
| SCHEMBL20929040 | 0.76 | KMO (0.49) | KMO | |
| Hydrochloric Acid SCHEMBL21173938 | 0.76 | KDM4E (0.53) | KMOKDM4EKDM6BTET3KDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117120430-A | MK2 inhibitors and uses thereof | 新特拉有限公司 | 2023-11-24 | — | — | CN | disclosed |
| WO-2023114977-A1 | S1PR4 RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | TIAKI THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20210214364-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2021-07-15 | — | — | US | disclosed |
| EP-3092231-B1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS INC (US) | 2018-06-27 | — | — | EP | disclosed |
| US-9856210-B2 | Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis | KYOTO UNIVERSITY (JP) | 2018-01-02 | — | — | US | disclosed |
| EP-2611437-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | UNIV KYOTO (JP) | 2017-03-29 | — | — | EP | disclosed |
| EP-3092231-A1 | SGC STIMULATORS | Ironwood Pharmaceuticals, Inc. (US) | 2016-11-16 | — | — | EP | disclosed |
| US-20160311826-A1 | SGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2016-10-27 | — | — | US | disclosed |
| WO-2015089182-A1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20130225642-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2013-08-29 | — | — | US | disclosed |
| WO-2012029994-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2012-03-08 | — | — | WO | disclosed |
| CN-101372475-B | Aromatic heterocyclic substituted diphenyl urea derivative and application thereof | NANJING UNIVERSITY OF TECHNOLOGY | 2012-01-04 | — | — | CN | disclosed |
| WO-2011025938-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| US-20090325145-A1 | METHODOLOGY FOR ANALYSIS OF SEQUENCE VARIATIONS WITHIN THE HCV NS5B GENOMIC REGION | INNOGENETICS N.V. (BE) | 2009-12-31 | — | — | US | disclosed |
| EP-2121990-A2 | METHODOLOGY FOR ANAYSIS OF SEQUENCE VARIATIONS WITHIN THE HCV NS5B GENOMIC REGION | Innogenetics N.V. (BE) | 2009-11-25 | — | — | EP | disclosed |
| CN-101372475-A | Aromatic heterocyclic substituted diphenyl urea derivative and application thereof | NANJING UNIVERSITY OF TECHNOLOGY (CN) | 2009-02-25 | — | — | CN | disclosed |
| WO-2008046922-A2 | METHODOLOGY FOR ANAYSIS OF SEQUENCE VARIATIONS WITHIN THE HCV NS5B GENOMIC REGION | INNOGENETICS N.V. (BE) | 2008-04-24 | — | — | WO | disclosed |
| US-6337368-B1 | WATER INSOLUBLE CARRIERS WITH P-NITROBENZOIC ACID, AROMATIC AMINES, AMIDES, SULFONAMIDES AND HYDRAZIDES | KANEKA CORPORATION (JP) | 2002-01-08 | — | — | US | disclosed |
| US-6174890-B1 | A SYNERGISTIC BIOLOGICAL, NEUROMETABOLIC AND CELLTROPHIC COMPOSITION COMPRISING ANTIOXIDATIVE AND -CATABOLIC STRESS (METHIONINE),-ANABOLIC DRUGS, VASODILATIVE AND NORMO-LIPIDEMIC DRUGS (NICOTINIC ACID), ENERGOACTIVE AND ANTITOXIC | RIGA DAN (RO) | 2001-01-16 | — | — | US | disclosed |
| EP-1008383-A1 | LIPOPROTEIN ADSORBENT AND LIPOPROTEIN ADSORBER MADE WITH THE USE OF THE SAME | KANEKA CORPORATION (JP) | 2000-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225642-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | SMN1; SMN2, SOD1, SOD3 | KMO 2484/4885KDM4E 2214/4885KDM6B 1524/4885 |
| US-20160311826-A1 | SGC STIMULATORS | GUCY1A1, GUCY1B1, GUCY1A2 | KMO 1564/4885KDM4E 1072/4885KDM6B 1068/4885 |
| US-20210214364-A1 | sGC STIMULATORS | GUCY1B1, GUCY1A1, GUCY1B2 | KMO 2612/4885KDM4E 871/4885KDM6B 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.